Hereditary angioedema due to C1-Inhibitor Deficiency (Type I or Type II) research hub

A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II)

This study is testing a new medicine, PHA-022121, for people with hereditary angioedema (HAE) Type 1 or 2. We want to see if it can help prevent swelling attacks. Participants will take either the new medicine or a dummy pill, and we'll compare how many attacks they have.